Dysmenorrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Sept. 23, 2011 - PRLog -- GlobalData estimates that the global dysmenorrhea therapeutics market was valued at $4.1 billion in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% over the next eight years to reach $4.8 billion by 2018. This low value growth in the dysmenorrhea therapeutics market is primarily attributed to the high usage of low priced OTC (Over-The-Counter) and off-label drugs and the low penetration of the patented product Celebrex (celecoxib). However, an increase in the patient population will be the primary contributor to the growth of the market in the forecast period.

GlobalData has found that the dysmenorrhea therapeutics market has a low unmet need, which implies
that the market is well-served by the current marketed products and that potential market entry for new drugs is limited. The current dysmenorrhea treatment options are mainly dominated by OTC, off-label and generic drugs which have high safety and efficacy profiles and capture a large market share.

However, the residual unmet need can be satisfied by novel therapies which will provide better
symptomatic relief than the current marketed products.

GlobalData’s analysis indicates that there will be not a significant change in the future landscape of the
dysmenorrhea therapeutics market. This is mainly attributed to the established treatment therapies, which include generics, OTC and off-label drugs that are successfully meeting market demand. The other factor is the weak pipeline with only a few first-in-class molecules in early stages of development. However, the few therapies in the pipeline that are expected to enter the market are me-too and generic products which will simply add to the existing competition in the market. This is expected to lead to a static market with products fighting for market share.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

GlobalData analysis shows that the dysmenorrhea therapeutics pipeline is weak with only eight molecules in different phases of development. There are five first-in-class molecules which are in the early stage of development; meaning that they are not expected to impact the market during the forecast period to 2018. The late stage pipeline does not have any molecules with novel mechanisms of action that may impact upon market. NPC-01, the only product in the late stage clinical development, is being developed for endometriosis associated dysmenorrhea and is not expected to significantly impact upon the overall dysmenorrheal market.

GlobalData, the industry analysis specialist, has released its new report, “Dysmenorrhea Therapeutics – Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global therapeutics market. The report identifies the key trends shaping and driving the global restless leg syndrome therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global restless leg syndrome therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Dysm...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.